1. At a Glance – Herbal Healing or Financial Fever?
Kerala Ayurveda Ltd is currently trading at ₹230, with a modest market cap of ₹277 Cr. Sounds peaceful, like a spa retreat in Wayanad. But look under the tulsi leaves and things get spicy.
The stock has crashed 42% in the last 3 months and is down 32.8% over 1 year. Return over 6 months? A brutal -55.2%. Investors who entered for “natural wellness” are currently experiencing “natural stress.”
Latest quarterly numbers (Dec 2025):
- Sales: ₹32.96 Cr
- PAT: -₹4.60 Cr
- ROCE: -9.01%
- ROE: -99.2%
- Debt: ₹84.6 Cr
- Debt to Equity: 15.5
- Price to Book: 50.7
Yes, you read that right. Fifty. Point. Seven.
The company that makes immunity boosters is itself financially immunocompromised.
And just when you think things can’t get more dramatic — promoter holding has fallen from 61.52% (Mar 2023) to 33.14% (Dec 2025). Public holding? Now 66.59%.
Is this a turnaround herbal tonic? Or a case study in balance sheet detox?
Let’s open the Ayurvedic manuscript.
2. Introduction – 80-Year-Old Brand, Teenage Financial Behaviour
Founded in 1945, Kerala Ayurveda Ltd is older than independent India. Which means this company has survived British Raj, License Raj, Liberalization, and now… negative ROE.
The business sounds dreamy:
- 350+ formulations
- Clinics, hospitals, wellness resorts
- Herb cultivation (1,200+ herbs!)
- Ayurveda academy in India & US
- US subsidiaries
- Singapore presence
Basically, if Ayurveda had LinkedIn, Kerala Ayurveda would be “Open to Work.”
But here’s the catch.
While revenues have grown from ₹93 Cr (FY23) to ₹126 Cr (FY25) and now ₹128 Cr TTM, profits have vanished like camphor in a temple aarti.
TTM PAT? -₹24 Cr.
TTM EPS? -₹20.22.
And when EPS is negative, P/E politely refuses to exist.
The company announced Vision 2030 — aiming for ₹1000 Cr revenue by 2030.
Ambition is good. But when current revenue is ₹128 Cr and debt is ₹84.6 Cr, the real question is:
Will this be an expansion journey… or a financial yatra?
3. Business Model – WTF Do They Even Do?
Let’s decode this herbal thali.
Segment-wise (FY23)
- Sale of Products – 61%
- Treatment Income – 22%
- Training Income –
